ArticleEuropean journal of medical research2022

EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms.

Pingan Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.